March 29, 2024
Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test
![](https://cdn.prod.website-files.com/650d8cdf0d3e3d0c6f9f1d19/660d48047e35ac5c57ba9383_TCL-logo_1200x627.jpg)
Original source here.
A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.
Recent news
Read all news